In the latest move to advance regulatory reliance in Brazil, the country’s medicines regulator, Anvisa, has approved new guidance setting out criteria for making use of pre- and post-market drug evaluations carried out by the foreign authorities it deems to be “equivalent” regulatory bodies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?